Metabolic effects of nandrolone decanoate and resistance training in men with HIV

American Journal of Physiology - Endocrinology and Metabolism

Volumn 283, Issue 6 46-6, 2002, Pages

  Sattler, Fred R ^a,c   Todd Schroeder, E ^a   Dube, Michael P ^a   Victoria Jaque, S ^a   Martinez, Carmen ^a   Blanche, Patricia J ^b   Azen, Stanley ^a   Krauss, Ronald M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c NONE   (United States)

Author keywords

Anabolic steroids; Androgen therapy; High density lipoprotein cholesterol; Insulin resistance; Lipoprotein(a); Low density lipoprotein cholesterol; Serum triglycerides

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANDROLONE DECANOATE; TRIACYLGLYCEROL;

ADULT; ANDROGEN THERAPY; ARTICLE; BODY FAT; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENERGY EXPENDITURE; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID METABOLISM; MALE; MUSCLE MASS; MUSCLE STRENGTH; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRAINING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036889317     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00189.2002     Document Type: Article

References (60)

1. Albers JJ, Taggart HM, Applebaum-Bowden D, Haffner S, Chesnut CH III, and Hazzard WR. Reduction of lecithincholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta 795: 293-296, 1984.
2. Allayee H, Dominguez KM, Aouizerat BE, Krauss RM, Rotter JI, Lu J, Cantor RM, de Bruin TW, and Lusis AJ. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. J Lipid Res 41: 245-252, 2000.
3. Assmann G, Schulte H, and von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77: 1179-1184, 1996.
4. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, and Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 260: 1917-1921, 1988.
5. Austin MA, Hokanson JE, and Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81: 7B-12B, 1998.
6. Austin MA and Krauss RM. Genetic control of low-densitylipoprotein subclasses. Lancet 2: 592-595, 1986.
7. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, and Bremner WJ. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 79: 561-567, 1994.
8. Ballantyne FC, Clark RS, Simpson HS, and Ballantyne D. High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects. Metabolism 31: 433-437, 1982.
9. Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, and Beall G. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. J Am Med Assoc 283: 763-770, 2000.
10. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, and Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281: E1172-E1181, 2001.
11. Campos H, Roederer GO, Lussier-Cacan S, Davignon J, and Krauss RM. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 15: 1043-1048, 1995.
12. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 353: 2093-2099, 1999.
13. Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski JS, Ponce AT, Heber D, and Block JB. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 58: 183-186, 1986.
14. Crook D, Sidhu M, Seed M, O'Donnell M, and Stevenson JC. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 92: 41-47, 1992.
15. Dahlen GH, Weinehall L, Stenlund H, Jansson JH, Hallmans G, Huhtasaari F, and Wall S. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med 244: 425-430, 1998.
16. Demling RH and Orgill DP. The anticatabolic and wound healing effects of the testosterone analog oxandrolone after severe burn injury. J Crit Care 15: 12-17, 2000.
17. Diamond MP, Grainger D, Diamond MC, Sherwin RS, and DeFronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 83: 4420-4425, 1998.
18. Edwards KL, Mahaney MC, Motulsky AG, and Austin MA. Pleiotropic genetic effects on LDL size, plasma triglyceride, and HDL cholesterol in families. Arterioscler Thromb Vasc Biol 19: 2456-2464, 1999.
19. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, Lieberman SA, Tipton K, Wolfe RR, and Urban RJ. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 282: E601-E607, 2002.
20. Friedewald WT, Levy RI, and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972.
21. Friedl KE, Hannan CJ Jr, Jones RE, and Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 39: 69-74, 1990.
22. Gardner CD, Fortmann SP, and Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. J Am Med Assoc 276: 875-881, 1996.
23. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 151: 1925-1933, 1991.
24. Glazer G and Suchman AL. Lack of demonstrated effect of nandrolone on serum lipids. Metabolism 43: 204-210, 1994.
25. Goldberg AP, Busby-Whitehead MJ, Katzel LI, Krauss RM, Lumpkin M, and Hagberg JM. Cardiovascular fitness, body composition, and lipoprotein lipid metabolism in older men. J Gerontol A Biol Sci Med Sci 55: M342-M349, 2000.
26. Grinspoon S, Corcoran C, Parlman K, Costello M, Rosenthal D, Anderson E, Stanley T, Schoenfeld D, Burrows B, Hayden D, Basgoz N, and Klibanski A. Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial. Ann Intern Med 133: 348-355, 2000.
27. Haffner SM, Mykkanen L, Valdez RA, Paidi M, Stern MP, and Howard BV. LDL size and subclass pattern in a biethnic population. Arterioscler Thromb 13: 1623-1630, 1993.
28. Hassager C, Podenphant J, Riis BJ, Johansen JS, Jensen J, and Christiansen C. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women. Metabolism 38: 238-242, 1989.
29. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, and Montanera JS. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 15: 231-239, 2001.
30. Hromadova M, Hacik T, Malatinsky E, Sklovsky A, and Cervenakov I. Some measures of lipid metabolism in young sterile males before and after testosterone treatment. Endocrinol Exp 23: 205-211, 1989.
31. Jaque S, Schroeder E, Azen S, Dube M, Olson C, Afghani A, Wiswell R, and Sattler F. Regional body composition changes during anabolic therapy. Clin Exercise Physiol 4: 50-59, 2002.
32. Johansen KL, Mulligan K, and Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. J Am Med Ass 281: 1275-1281, 1999.
33. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, and Quon MJ. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: 2402-2410, 2000.
34. Katzel LI, Krauss RM, and Goldberg AP. Relations of plasma TG and HDL-C concentrations to body composition and plasma insulin levels are altered in men with small LDL particles. Arterioscler Thromb 14: 1121-1128, 1994.
35. Koppel K, Bratt G, Eriksson M, and Sandstrom E. Serum lipid levels associated with increased risk for cardiovascular disease are associated with highly active antiretroviral therapy (HAART) in HIV-1 infection. Int J STD AIDS 11: 451-455, 2000.
36. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, and Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study. Circulation 100: 1154-1160, 1999.
37. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 137: 959-965, 1993.
38. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, and Despres JP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 95: 69-75, 1997.
39. Lansang MC, Williams GH, and Carroll JS. Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens 14: 51-53, 2001.
40. Laws A and Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. J Intern Med 231: 25-30, 1992.
41. Lippi G, Guidi G, Ruzzenente O, Braga V, and Adami S. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest 57: 507-511, 1997.
42. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, and Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J Am Med Assoc 274: 1771-1774, 1995.
43. Marin P. Testosterone and regional fat distribution. Obes Res 3, Suppl 4: 609S-612S, 1995.
44. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, Schiff ER, McClain CJ, Marsano LS, and Allen JI. Protein energy malnutrition in severe alcoholic hepatitis: Diagnosis and response to treatment. The VA Cooperative Study Group #275. J Parenter Enteral Nutr 19: 258-265, 1995.
45. Miller NE, Hammett F, Saltissi S, Rao S, van Zeller H, Coltart J, and Lewis B. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J (Clin Res Ed) 282: 1741-1744, 1981.
46. Nichols AV, Krauss RM, and Musliner TA. Non-denaturing polyacylamide gradient gel electrophoresis. In: Methods in Enzymology: Plasma Lipoproteins, edited by JP Segrist and JJ Albers. New York: Academic, 1986, p. 417-431.
47. Nishina PM, Johnson JP, Naggert JK, and Krauss RM. Linkage of atherogenic lipoprotein phenotype to the low density lipoprotein receptor locus on the short arm of chromosome 19. Proc Natl Acad Sci USA 89: 708-712, 1992.
48. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C, and Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS (Phila) 14: 51-57, 2000.
49. Reaven GM, Chen YD, Jeppesen J, Maheux P, and Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92: 141-146, 1993.
50. Sattler FR, Jaque SV, Schroeder ET, Olson C, Dube MP, Martinez C, Briggs W, Horton R, and Azen S. Effects of pharmacological doses of nandrolone decanoate and progressive resistance training in immunodeficient patients infected with human immunodeficiency virus. J Clin Endocrinol Metab 84: 1268-1276, 1999.
51. Schols AM, Soeters PB, Mostert R, Pluymers RJ, and Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 152: 1268-1274, 1995.
52. Schroeder E, Jaque S, Hawkins S, Olson C, Wiswell R, and Sattler F. Regional DXA and MRI in assessment of muscle adaptations to anabolic stimuli. Clin Exercise Physiol 3: 199-206, 2001.
53. Sheffield-Moore M, Urban RJ, Wolf SE, Jiang J, Catlin DH, Herndon DN, Wolfe RR, and Ferrando AA. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab 84: 2705-2711, 1999.
54. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, and Hulley SB. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. J Am Med Assoc 283: 1845-1852, 2000.
55. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, Shen R, Bross R, Berman N, and Bhasin S. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 87: 136-143, 2002.
56. Snyder PJ, Peachy H, Hannoush P, Berlin JA, Loh L, Lenrow DA, Holmes JH, Dlewati A, Santanan J, Rosen CJ, and Strom BL. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 84: 2647-2653, 1999.
57. Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, and Dabis F. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine cohort, France, 1999. Clin Infect Dis 31: 1482-1487, 2000.
58. Thompson PD, Cullinane EM, Sady SP, Chenevert C, Saritelli AL, Sady MA, and Herbert PN. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. J Am Med Assoc 261: 1165-1168, 1989.
59. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, and Ferrando A. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol Endocrinol Metab 269: E820-E826, 1995.
60. Williams PT, Dreon DM, and Krauss RM. Effects of dietary fat on high-density-lipoprotein subclasses are influenced by both apolipoprotein E isoforms and low-density-lipoprotein subclass patterns. Am J Clin Nutr 61: 1234-1240, 1995.